The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this ...

Avisi Technologies’ investigational device exemption (IDE) submission for its glaucoma treatment device VisiPlate has been approved by the US Food and Drug Administration (FDA).

Micro Interventional Devices (MID), a pioneering company in Transcatheter Tricuspid Valve Repair (TTVr) developing MIA-T ...

Deaths of despair spiked during Covid and continue to have lasting effects on our families, children and teens. Awareness and ...

A new trivalent vaccine shows promise in preventing typhoid and invasive Salmonella infections with strong immune response in ...

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025/CNW/ — Eight new oncology approvals between July and September 2025 marked a pivotal quarter ...

Patient selection should prioritize those with obesity and heart failure with preserved ejection fraction, as benefits for ...

Former cadets accuse Maryland’s National Guard Freestate ChalleNGe Academy of abuse, unsafe conditions and a lack of ...

Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the ...

Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet.

Myeloid Therapeutics has rebranded as Create Medicines and unveiled a drug development strategy adding to its initial emphasis on cancer treatments.